Biohaven ' s NURTEC ™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news